We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

33 hedge funds and large institutions have $7.58M invested in Protalix BioTherapeutics in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 5

13% more call options, than puts

Call options by funds: $2.86M | Put options by funds: $2.53M

10.43% less ownership

Funds ownership: 19.94% → 9.51% (-10%)

13% less funds holding

Funds holding: 38 → 33 (-5)

36% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 14

81% less capital invested

Capital invested by funds: $39.4M → $7.58M (-$31.8M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
33
Holders Change
-5
Holders Change %
-13.16%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
9
Increased
12
Reduced
5
Closed
14
Calls
$2.86M
Puts
$2.53M
Net Calls
+$332K
Net Calls Change
+$481K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$6.41M
2
Walleye Capital
Walleye Capital
New York
+$1.19M
3
MIH
Meitav Investment House
Israel
+$841K
4
Group One Trading
Group One Trading
Illinois
+$616K
5
Walleye Trading
Walleye Trading
New York
+$465K

Top Sellers

Rank Fund Capital Flow
1
PVH
Psagot Value Holdings
Israel
-$10.6M
2
BCM
Burrage Capital Management
Massachusetts
-$9.48M
3
DCM
DAFNA Capital Management
California
-$5.37M
4
UOC
UBS O'Connor
Illinois
-$1.99M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
FDCDDQ
26
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.1K – – –
CAPTRUST Financial Advisors
27
CAPTRUST Financial Advisors
North Carolina
$2K – – –
GAM
28
Gemmer Asset Management
California
$2K – – –
SPIA
29
Steward Partners Investment Advisory
New York
$2K – – –
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$2K +$1.72K +500 +81%
Deutsche Bank
31
Deutsche Bank
Germany
$2K +$3K +873 New
TCWA
32
Ten Capital Wealth Advisors
Washington
$1K +$430 +125 +63%
Walleye Capital
33
Walleye Capital
New York
$662 +$1.19M +346,539 New
BCM
34
Burrage Capital Management
Massachusetts
– -$9.48M -2,125,585 Closed
DCM
35
DAFNA Capital Management
California
– -$5.37M -1,204,825 Closed
UOC
36
UBS O'Connor
Illinois
– -$1.99M -445,171 Closed
DADC
37
D.A. Davidson & Co
Montana
– -$583K -130,700 Closed
Osaic Holdings
38
Osaic Holdings
Arizona
– -$545K -122,184 Closed
SSA
39
Schonfeld Strategic Advisors
New York
– -$399K -89,278 Closed
California Public Employees Retirement System
40
California Public Employees Retirement System
California
– -$297K -66,631 Closed
LCM
41
Laurion Capital Management
New York
– -$191K -42,813 Closed
VF
42
Virtu Financial
New York
– -$124K -27,744 Closed
Capstone Investment Advisors
43
Capstone Investment Advisors
New York
– -$94K -21,058 Closed
GSC
44
Ground Swell Capital
South Carolina
– -$65K -14,684 Closed
WP
45
WealthShield Partners
North Carolina
– -$13K -3,000 Closed
JP Morgan Chase
46
JP Morgan Chase
New York
– -$6K -1,293 Closed
APC
47
Aspire Private Capital
North Carolina
– -$2K -400 Closed
1
2

PLX Hedge Fund Activity: Q2 2021 in Review

33 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2021, worth a combined $7.58M — down 81% from $39.4M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of PLX and 9 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 12 added.

The largest buyer was Morgan Stanley, adding an estimated $6.41M. The largest seller was Psagot Value Holdings, cutting an estimated $10.6M.

  • 33 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2021, down from 38 in Q1 2021.
  • Funds reported $7.58M of Protalix BioTherapeutics stock for Q2 2021, down 81% quarter-over-quarter.
  • 9 funds opened new Protalix BioTherapeutics positions in Q2 2021 and 14 closed out, a net change of -5 holders.
  • The largest Protalix BioTherapeutics buyer in Q2 2021 was Morgan Stanley, an estimated $6.41M added.
  • The largest Protalix BioTherapeutics seller in Q2 2021 was Psagot Value Holdings, an estimated $10.6M sold.

Based on aggregated 13F filings for Q2 2021.